Journal of Hematology & Thromboembolic Diseases
Open Access
ISSN: 2329-8790
+44 1478 350008
ISSN: 2329-8790
+44 1478 350008
Rym EL FATMI
University Tunis EL MANAR, Tunisia
Scientific Tracks Abstracts: J Hematol Thromb Dis
Background: Patients with hematologic malignancies (HM) are considered vulnerable to severe COVID19 infection due to their underlying malignancy and their anticancer therapy. Aims: To determine the clinical and biological caracteristics of COVID19 infection in HM and the risk factors of COVID19 severity and mortality. Results: 68 patients was included. Median age was 47 years, sex ratio: 1.5. Patients were treated for acute leukemia;43%, lymphoma; 37%,CLL; 9%, myeloma;9%, and MDS; 4%. 63% had active disease (AD) while 37% were in remission (RD). Thirty-three patients (46%) had at last 1 comorbidity. The main symptoms of the infection were fever (63%), cough (49%), dyspnea (40%) and diarrhea (30%). Seventeen patients had a chest scanning, 12 (70%) of them had a damage >25% of the lungs (60% and 85% in the AD and RD groups respectively [p=0.15]). During the infection, 44% of patients had lymphopenia and 21% grade 4 neutropenia. Median CRP was of 154 mg/l [1.9-658]. Twenty (29%) patients developped severe infection (37% and 16% in the AD and RD groups respectively [p=0.09]). Seven required admission in an ICU (14% and 4% of the AD and RD groups respectively[p=0.14]). Significant risk factors of the severity of the infection were : age >45 years (p= 0.008), ≥1comorbidity (p=0.009), dyspnea (p< 0.0001) and CRP >150 mg/l (p =0.033). Twelve patients (18%) died from COVID19 infection (23% and 8% in the AD and RD groups respectively[p=0.11]). Dyspnea and grade 4 neutropenia were the independent risk factors of death (p=0.011 and p=0.049 respectively). Conclusion: High rates of COVID19 infection severity and associated mortality was noted especially in neutropenic patients. Although no difference was observed in the radiological severity between AD and RD groups, there was a trend to a more clinically severe infection in the AD group.
Rym EL FATMI has completed her PhD at the age of 29 years and a Master’s Degree in Intensive Care in Infectious Pathologies and a Master’s Degree in Chronic Pains from the Faculty of Medecine of Tunis, Tunisia and a Master’s Degreee in Transfusion, Hemobiology and Cellular Therapy from Faculty of Pharmacy of Monastir, Tunisia and a Postgraduate Diploma in Leadership and Management in Health from the University of Washington.